MedPath

Sodium Bicarbonate Ringer's Solution for Preventing and Treating Hyperlactacidemia During Hepatectomy

Not Applicable
Conditions
Hyperlactacidemia
Interventions
Drug: Sodium Bicarbonate Ringer's Solution
Registration Number
NCT04547296
Lead Sponsor
First Affiliated Hospital Xi'an Jiaotong University
Brief Summary

A variety of reasons lead to a sharp increase in lactic acid levels in patients undergoing liver resection, while leading to hyperlactic acidemia, resulting in decreased cardiac output, elevated blood potassium, and response to catecholamines and insulin Damage, increased risk of kidney damage, poor recovery of liver function, decreased immune function, and prolonged hospital stay. Sodium bicarbonate Ringer injection does not contain lactic acid. HCO3- is metabolized by acid-base neutralization in body fluids, and 90% is CO2 The form is excreted from the body by breathing, and only 10% HCO3- is metabolized by the kidney, without the burden of liver metabolism. Physiological concentration of Cl- avoids perchloric acidosis and kidney damage; physiological concentration of Ca2+ and Mg2+ help maintain the body's electrolyte balance and reduce stress-related arrhythmia.The smooth development of this study will help refine the intraoperative fluid management strategy, improve the patient's intraoperative tissue perfusion, maintain the body's acid-base and electrolyte balance, reduce postoperative kidney damage, and improve the patient's quality of life.

Detailed Description

This study intends to carry out a high-quality clinical research with design specifications, large sample, multi-center, randomized and controlled methods. From October 9, 2020 to October 9, 2022, participants undergoing hepatectomy surgery under general anesthesia will be recruited. Participants will be randomly assigned, in a 1:1 ratio, to receive Sodium bicarbonate Ringer's solution or control (Acetate Ringer's solution). The randomization sequence will be computer-generated, and randomization will be performed in blocks and will be stratified according to participating center. After entering the operating room, the two groups were pre-dilated with sodium bicarbonate Ringer or acetate Ringer (30 min, 8 ml/kg). After the operation started, the two groups of participants were maintained with 4-5 ml/kg/h Ringer's solution during the operation. Blood gas index (but are not limited to these data) at intraoperative will be recorded. At the same time, other dates will be recorded.The participation of each patient is scheduled for 1 month.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
484
Inclusion Criteria
  1. Patients for selective liver surgery under general anesthesia
  2. Age > 18 year,BMI 18 - 40 kg/m2,American society of Anesthesiologists (ASA) grade are between I - III
  3. Ability to understand, sign informed consent and cooperate with the intervention and evaluation
Exclusion Criteria
  1. Abnormal renal function:blood creatinine (Cr) and / or urea nitrogen (BUN)> upper limit of normal value; Patients with underlying kidney disease; patients with congenital kidney malformations.
  2. In patients with respiratory failure, arterial blood oxygen partial pressure (PaO2) < 60 mmHg, or accompanied by carbon dioxide partial pressure (PaCO2)> 50mmHg; blood oxygen saturation (SpO2) < 90%.
  3. A history of myocardial infarction within 6 months before the screening period; history of severe circulatory or respiratory diseases; history of autoimmune diseases; patients with mental illness or neurological disorders that cannot be expressed exactly; patients with a history of epilepsy; patients with pulmonary edema or congestive heart failure.
  4. Severe hypercalcemia (Ca2+ > 2.75 mmol/L), hypernatremia (Na+ > 155 mmol/L), hyperkalemia (K+ > 5.5 mmol/L), hyperchloremia (Cl- > 110 mmol/L), Hypermagnesium (Mg2+ > 1.25 mmol/L).
  5. Patients with a history of hypothyroidism; pregnant or lactating women.
  6. Patients with a history of adverse blood transfusion reactions; those who refuse blood transfusions.
  7. Participation in other clinical studies within 3 months before admission to this study.
  8. The investigator considers it unsuitable for inclusion.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
BRS groupSodium Bicarbonate Ringer's SolutionAfter entering the operating room, this group were pre-dilated with sodium bicarbonate ringer's solution (30 min, 8 ml/kg), and maintained with 4-5 ml/kg/h sodium bicarbonate ringer's solution during the operation.
ARS groupSodium Bicarbonate Ringer's SolutionAfter entering the operating room, this group were pre-dilated with acetate ringer ringer's solution (30 min, 8 ml/kg), and maintained with 4-5 ml/kg/h acetate ringer's solution during the operation.
Primary Outcome Measures
NameTimeMethod
Incidence of intraoperative hyperlactacidemiaDuring the operation

Diagnostic criteria: Lac ≥ 2 mmol/L, pH ≤ 7.35, HCO3- ≤ 20 mmol/L, PaCO2 \<50 mmHg

Secondary Outcome Measures
NameTimeMethod
Incidence of postoperative acute kidney injuryDay 2 after the operation

The incidence of acute kidney injury within 48h after surgery was recorded

Rate of postoperative complicationsDay 30 after the operation

postoperative complications: cardiovascular complications; pulmonary complications; infection complications; other complications

The incidence of blood gas index disorderDuring the operation

Blood gas was monitored every hour during the operation and the incidence of intraoperative blood gas index disorder was recorded

Trial Locations

Locations (7)

Henan Cancer Hospital

🇨🇳

Zhengzhou, Henan, China

Henan Provincial People's Hospital

🇨🇳

Zhengzhou, Henan, China

The First Hospital of Lanzhou University

🇨🇳

Lanzhou, Gansu, China

Qinghai University Affiliated Hospita

🇨🇳

Xining, Qinghai, China

The First Affiliated Hospital of Xinjiang Medical University

🇨🇳

Ürümqi, Xinjiang, China

People's Hospital of Xinjiang Uygur Autonomous Region

🇨🇳

Ürümqi, Xinjiang, China

Shaanxi Provincial People's Hospital

🇨🇳

Xi'an, Shaanxi, China

© Copyright 2025. All Rights Reserved by MedPath